A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

NCT03231800 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention-Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG: dasotraline
DRUG: Placebo

Sponsor

Sumitomo Pharma America, Inc.